| Original language | English |
|---|---|
| Pages (from-to) | E209-E213 |
| Journal | American Journal of Hematology |
| Volume | 94 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2019 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: American Journal of Hematology, Vol. 94, No. 8, 08.2019, p. E209-E213.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy
AU - Chow, Victor A.
AU - Gopal, Ajay K.
AU - Maloney, David G.
AU - Turtle, Cameron J.
AU - Smith, Stephen D.
AU - Ujjani, Chaitra S.
AU - Shadman, Mazyar
AU - Cassaday, Ryan D.
AU - Till, Brian G.
AU - Tseng, Yolanda D.
AU - Warren, Edus H.
AU - Shustov, Andrei R.
AU - Menon, Manoj P.
AU - Bhark, Sandra
AU - Acharya, Utkarsh H.
AU - Mullane, Erin
AU - Hannan, Lindsay M.
AU - Voutsinas, Jenna M.
AU - Gooley, Ted A.
AU - Lynch, Ryan C.
N1 - Funding Information: This work was supported by 5K24CA184039, T32CA009515, donations from Frank and Betty Vandermeer and Sonya and Tom Campion. Funding Information: V.A.C. has no disclosures. A.K.G. reports grants and nonfinancial support from Teva, Bristol-Myers Squibb, Merck, Takeda, TG Therapeutics, and Effector; grants, personal fees, and nonfinancial support from Seattle Genetics, Pfizer, Janssen, Gilead, Spectrum, Amgen and Incyte; personal fees from Aptevo, BRIM Bio, Seattle Genetics and Sanofi. D.J.M. reports honoraria from Celgene, Gilead Sciences, Kite Pharma, Roche and research funding from Juno Therapeutics. C.J.T. receives research funding from Juno Therapeutics/Celgene and Nektar Therapeutics, has patents licensed to Juno Therapeutics/Celgene, has served on advisory boards and has options in Precision Biosciences, Eureka Therapeutics, and Caribou Biosciences, and has served on advisory boards for Nektar Therapeutics, Aptevo, Kite/Gilead, Novartis, and Juno Therapeutics/Celgene. S.D.S. reports funding from Astra Zeneca, Acerta Pharma, Genentech Research, Incyte Corporation, Merck Sharp and Dohme Corporation, Pharmacyclics, Portola Pharmaceuticals, Seattle Genetics and provides consultancy for Astra Zeneca and Merck Sharp and Dohme Corporation. C.S.U. has no disclosures. M.S. provides consultancy for Abbvie, Genentech, Sound Biologics, is on the advisory board for Abbvie, Genentech, Veras-tem, ADC Therapeutics and has research funding from Mustang Biopharma, Celgene, Pharmacyclics, Gilead, Genentech, TG therapeutics, Bigene, Acerta Pharma, Emergent, Merck. R.D.C. has received research funding from Amgen, Kite/Gilead, Merck, and Pfizer, and has served as a consultant/advisor to Adaptive Biotechnologies, Amgen, Pfizer, and Jazz Pharmaceuticals. B.G.T. reports patents/royalties and research funding from Mustang Bio. Y.D.T. has no disclosures. E.H.W. has no disclosures. A.R.S. has no disclosures. M.P.M. has no disclosures. S.K. has no disclosures. U.H.A. received research support from JUNO Therapeutics and provides consultancy for Celgene, Teva, Kite. E.M. has no disclosures. L.M.H. has no disclosures. J.M.V. has no disclosures. T.G. has no disclosures. R.C.L. reports
PY - 2019/8
Y1 - 2019/8
UR - https://www.scopus.com/pages/publications/85066906193
U2 - 10.1002/ajh.25505
DO - 10.1002/ajh.25505
M3 - Letter
C2 - 31056762
AN - SCOPUS:85066906193
SN - 0361-8609
VL - 94
SP - E209-E213
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 8
ER -